Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283449 · ClinicalTrials.gov registry record · Phase 1
Tau PET Imaging in Atypical Dementias
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT03283449 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 70 participants.
The verdict
NCT03283449, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
Interventions
- DRUG 18F-AV-1451
- DEVICE PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-02 |
| Est. Completion | 2025-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283449
The ClinicalTrials.gov registry entry for NCT03283449 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 18F-AV-1451 is the first listed.
NCT03283449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03283449 about?
NCT03283449 is a clinical study titled "Tau PET Imaging in Atypical Dementias". The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techni...
What is the current status of trial NCT03283449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2016-02. Estimated completion is 2025-02-28.
What interventions are being tested in trial NCT03283449?
The interventions under investigation include: 18F-AV-1451 (DRUG), PET (DEVICE).
Who is sponsoring clinical trial NCT03283449?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.